(12) International Application Status Report

Received at International Bureau: 12 April 2020 (12.04.2020)

Information valid as of: 07 September 2020 (07.09.2020)

Report generated on: 28 January 2021 (28.01.2021)

(10) Publication number: (43) Publication date: (26) Publication language:
WO 2020/19868301 October 2020 (01.10.2020) English (EN)

(21) Application number: (22) Filing date: (25) Filing language:
PCT/US2020/02546927 March 2020 (27.03.2020) English (EN)

(31) Priority number(s): (32) Priority date(s): (33) Priority status:
62/825,726 (US)28 March 2019 (28.03.2019) Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:
A61K 31/5377 (2006.01)

(71) Applicant(s):
AB STUDIO INC. [US/US]; 3541 Investment Boulevard Suite 3 Hayward, California 94545 (US) (for all designated states)

(72) Inventor(s):
LIU, Yue; 815 Peary Lane Foster City, California 94404 (US)
DONG, Jianbo; 3692 Randolph Avenue Santa Clara, California 95051 (US)
WANG, Bo; 408 Portofino Drive, Unit 2 San Carlos, California 94070 (US)

(74) Agent(s):
QI, Yan; Morrison & Foerster LLP 755 Page Mill Road Palo Alto, California 94304-1018 (US)

(54) Title (EN): HETEROMULTIMERIC PROTEINS AND METHODS OF USE THEREOF
(54) Title (FR): PROTÉINES HÉTÉROMULTIMÈRES ET LEURS MÉTHODES D'UTILISATION

(57) Abstract:
(EN): The present application provides heteromultimenric proteins, such as bispecific antibodies, comprising a first antibody heavy chain constant domain 3 (CH3)-eontaining polypeptide having a substitution relative to a wildtype CH3 domain at amino acid position 354 with a bulky hydrophobic amino acid, and/or a second CH3 -containing polypeptide comprising a substitution relative to a wildtype CH3 domain at ammo acid position 347 with a negatively charged ammo acid residue. Also provided are polypeptides, nucleic acids and vectors encoding such polypeptides, pharmaceutical compositions, methods of preparation and methods of treatment using the heteromultimeric proteins.
(FR): La présente invention concerne des protéines hétéromultimères, telles que des anticorps bispécifiques, comprenant un premier polypeptide contenant un domaine 3 constant de chaîne lourde (CH3) d'anticorps, comportant une substitution par rapport à un domaine CH3 de type sauvage, à la position d'acide aminé 354, avec un acide aminé hydrophobe volumineux, et/ou un second polypeptide contenant CH3 comprenant une substitution par rapport à un domaine CH3 de type sauvage, à la position d'acide aminé 347, avec un résidu d'acide aminé chargé négativement. L'invention concerne également des polypeptides, des acides nucléiques et des vecteurs codant pour de tels polypeptides, des compositions pharmaceutiques, des procédés de préparation et des méthodes de traitement utilisant ces protéines hétéromultimères.

International search report:
Received at International Bureau: 05 September 2020 (05.09.2020) [US]

International Report on Patentability (IPRP) Chapter II of the PCT:
Not available

(81) Designated States:
AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW
European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG
African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW
Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM